THANK YOU FOR SUBSCRIBING
Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Healthcare Tech Outlook
THANK YOU FOR SUBSCRIBING
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info
Cota initially targeted cancer, however, CNAs are effective tools for any complex disease such as mental health, cardiology and rheumatology. “Unlike ‘big data’ plays in healthcare that look for patterns in large data sets, Cota starts with established patterns – and finds value,” said John Hervey, CEO of Cota Healthcare. Each digitized patient record is encapsulated in a numeric code that expresses all relevant elements in a patient’s record and treatment journey. This code can be used by hospitals and insurance companies to optimize care and simplify claims adjudications. The CNA includes a wide array of phenotypic patient data like tumor type, histology, comorbidities and patient-specific genomics that is not included in the current standards such as the ICD codes.
![]()
CNA is a very flexible way of looking at data sets from a multi-dimensional perspective
When Hackensack Meridian Health (HMH)—a NJ-based not-for-profit health care organization—set out to establish a value-based bundles program for its cancer center, they sought Cota’s assistance. Using its CNA Guided Care platform, Cota has worked closely with HMH to identify the best treatments for its patients then to use these results to optimize the cost efficiencies of its care. Cota has partnered with IBM Watson for Oncology to deliver its care solutions directly to physicians, nurses and other medical professionals at the point of patient care. This partnership combines the RWD and CNAs from Cota with the incomparable information suite and artificial intelligence platform of IBM Watson.
Cota already has a national footprint with its hospital partnerships and is working with seven of the top ten pharmaceutical companies. Hervey expects the demand for value based care solutions to rise significantly in the future and believes Cota has one of the only viable solutions for very complex diseases that optimizes outcomes rather than rationing care.